Table 5. Odds ratios of death among mechanically ventilated COVID-19 patients.
| Odds Ratio | P value | |
|---|---|---|
| (95% Confidence Interval) | ||
| Unadjusted: (N = 164) | ||
| Age | 1.07 (1.04–1.10) | <0.0001 |
| Male Gender | 0.75 (0.39–1.43) | 0.38 |
| Non-Caucasian Race (N = 161) | 0.47 (0.34–0.64) | <0.0001 |
| Hispanic Ethnicity | 0.45 (0.23–0.88) | 0.0170 |
| Tertiary Care Hospital | 0.51 (0.27–0.95) | 0.0332 |
| Enrollment in Clinical Trial | 0.46 (0.14–1.50) | 0.18 |
| ECMO | 0.28 (0.08–1.02) | 0.03 |
| Tocilizumab | 0.37 (0.18–0.76) | 0.0055 |
| Hydroxychloroquine | 0.51 (0.23–1.10) | 0.09 |
| *Adjusted: (N = 161) | ||
| Age | 1.06 (1.03–1.10) | <0.0001 |
| Non-Caucasian Race | 0.54 (0.38–0.77) | 0.001 |
| Tertiary Care Hospital | 0.44 (0.20–0.94) | 0.034 |
| Tocilizumab | 0.42 (0.18–0.98) | 0.045 |